USARx offers multiple ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about enoxaparin. Some of the dosage forms listed on this page may not apply to the brand name Lovenox.
Common side effects of Lovenox include: anemia and hemorrhage. Other side effects include: fever. See below for a comprehensive list of adverse effects.
Applies to enoxaparin: solution
Injection route (Solution)
Epidural or spinal hematomas, which may result in long-term or permanent paralysis, may occur in patients who are anticoagulated with low molecular weight heparins or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. Factors that can increase the risk of developing these hematomas include: use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis such as NSAIDs, platelet inhibitors, or other anticoagulants, or history of traumatic or repeated epidural or spinal puncture, spinal deformity, or spinal surgery. Optimal timing between the administration of enoxaparin sodium and neuraxial procedures is not known. Monitor patients frequently for neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider risks/benefits before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.
Along with its needed effects, enoxaparin (the active ingredient contained in Lovenox) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking enoxaparin:
Incidence not known
Some side effects of enoxaparin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to enoxaparin: injectable solution
The most common adverse reactions were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, and nausea.
Common (1% to 10%): Major hemorrhage
Uncommon (0.1% to 1%): Atrial fibrillation, heart failure
Frequency not reported: Hemorrhage
Postmarketing reports: Shock, valve thrombosis in patients with prosthetic heart valves
Common (1% to 10%): Thrombocytopenia, anemia, platelet counts between 100,000 and 50,000/mm3
Uncommon (0.1% to 1%): Platelet counts less than 50,000/mm3
Frequency not reported: Thrombocytosis
Postmarketing reports: Hemorrhagic anemia, platelet count increased, eosinophilia
Common (1% to 10%): ALT increased asymptomatically, AST increased asymptomatically
Frequency not reported: Hepatic enzymes increased
Postmarketing reports: Hepatocellular liver injury, cholestatic liver injury
Common (1% to 10%): Nausea, diarrhea
Uncommon (0.1% to 1%): Retroperitoneal hemorrhage
Common (1% to 10%): Injection site hematoma, injection site pain, other injection site reaction
Uncommon (0.1% to 1%): Local irritation, injection site skin necrosis
Postmarketing reports: Injection site nodules
Common (1% to 10%): Urticaria, pruritus, erythema
Uncommon (0.1% to 1%): Bullous dermatitis
Postmarketing reports: Cutaneous vasculitis, skin necrosis, alopecia
Common (1% to 10%): Peripheral edema, edema
Rare (less than 0.1%): Hyperkalemia
Postmarketing reports: Hyperlipidemia, hypertriglyceridemia
Common (1% to 10%): Allergic reaction
Rare (0.01% to 0.1%): Anaphylactic/anaphylactoid reaction
Very rare (less than 0.01%): Immuno-allergic thrombocytopenia
Postmarketing reports: Immuno-allergic thrombocytopenia with thrombosis
Common (1% to 10%): Dyspnea
Uncommon (0.1% to 1%): Lung edema, pneumonia
Uncommon (0.1% to 1%): Hematuria
Common (1% to 10%): Confusion
Common (1% to 10%): Fever
Uncommon (0.1% to 1%): Intracranial hemorrhage
Postmarketing reports: Headache, spinal hematoma
Postmarketing reports: Osteoporosis following treatment longer than 3 months